102 research outputs found

    Cognitive Information Processing

    Get PDF
    Contains reports on three research projects.National Institutes of Health (Grant 5 PO1 GM14940-03)National Institutes of Health (Grant 5 P01 GM15006-03)Joint Services Electronics Programs (U. S. Army, U. S. Navy, and U. S. Air Force) under Contract DA 28-043-AMC-02536(E

    Radio Astronomy

    Get PDF
    Contains reports on six research projects.National Aeronautics and Space Administration (Grant NsG-419)National Aeronautics and Space Administration (Contract NSR-22-009-120

    Radio Astronomy

    Get PDF
    Contains reports on seven research projects.U. S. Navy (Office of Naval Research) under Contract N00014-67-A-0204-0009National Aeronautics and Space Administration (Grant NsG-419)National Science Foundation (Grant GP-7046)National Aeronautics and Space Administration (Contract NSR-22-009-120)Joint Services Electronics Programs (U. S. Army, U. S. Navy, and U.S. Air Force, Under Contract DA 28-043-AMC-02536(E

    Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways

    Get PDF
    There is an unmet need in severe asthma where approximately 40% of patients exhibit poor β-agonist responsiveness, suffer daily symptoms and show frequent exacerbations. Antagonists of the Ca2+-activated Cl− channel, TMEM16A, offers a new mechanism to bronchodilate airways and block the multiple contractiles operating in severe disease. To identify TMEM16A antagonists we screened a library of ∼580,000 compounds. The anthelmintics niclosamide, nitazoxanide, and related compounds were identified as potent TMEM16A antagonists that blocked airway smooth muscle depolarization and contraction. To evaluate whether TMEM16A antagonists resist use- and inflammatory-desensitization pathways limiting β-agonist action, we tested their efficacy under harsh conditions using maximally contracted airways or airways pretreated with a cytokine cocktail. Stunningly, TMEM16A antagonists fully bronchodilated airways, while the β-agonist isoproterenol showed only partial effects. Thus, antagonists of TMEM16A and repositioning of niclosamide and nitazoxanide represent an important additional treatment for patients with severe asthma and COPD that is poorly controlled with existing therapies. It is of note that drug repurposing has also attracted wide interest in niclosamide and nitazoxanide as a new treatment for cancer and infectious disease. For the first time we identify TMEM16A as a molecular target for these drugs and thus provide fresh insights into their mechanism for the treatment of these disorders in addition to respiratory disease

    Infrared thermography for convective heat transfer measurements

    Get PDF
    • …
    corecore